NEW YORK, Jan. 27 (GenomeWeb News) - Quest Diagnostics has agreed to market Digene's DNA-based test for human papillomavirus (HPV), Digene said today.
Under the three-year agreement, Quest will offer physicians Digene's HPV test for routine cervical cancer screening in conjunction with the Pap test.
Quest previously provided the test to physicians only for follow-up evaluation of ambiguous Pap test results. Digene's HPV test was approved in March 2003 for primary cervical cancer screening, in conjunction with a Pap test, in women age 30 and over.
The American College of Obstetricians and Gynecologists, the American Cancer Society, and the Association of Reproductive Health Professionals each have updated their screening guidelines to include HPV DNA testing as part of routine cervical cancer screening for women age 30 and older, Digene said.